Allarity Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
Allarity Therapeutics, Inc. (ALLR) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 19.17 million shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-13.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2023-03-13
- Allarity Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2022-03-31 was 12.91M shares, a 811.89% increase year-over-year.
- Allarity Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2021-03-31 was 1.42M shares.
- Allarity Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2022 was 19.17M shares, a 269.29% increase from fiscal 2021.
- Allarity Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2021 was 5.19M shares, a 293.01% increase from fiscal 2020.
- Allarity Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2020 was 1.32M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2022-12-31 | 19.17M shares 10-K · filed 2023-03-13 | |||
| 2022-09-30 | 10.97M shares 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 12.31M shares 10-Q · filed 2022-10-07 | |||
| 2022-03-31 | 12.91M shares 10-Q · filed 2022-05-27 | |||
| 2021-12-31 | 5.19M shares 10-K · filed 2023-03-13 | |||
| 2021-09-30 | 233.47K shares 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 3.71M shares 10-Q · filed 2022-10-07 | |||
| 2021-03-31 | 1.42M shares 10-Q · filed 2022-05-27 | |||
| 2020-12-31 | 1.32M shares 10-K · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |